Roth Capital raised the firm’s price target on IperionX (IPX) to $74 from $64 and keeps a Buy rating on the shares. The firm cites the company’s FY25 results and the receipt of additional government funding as part of its existing $47.1M award, the analyst tells investors in a research note. Roth adds that its higher price target reflects lower future dilution assumptions and a higher multiple on 2029 EBITDA.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IPX:
- IperionX Ltd. ADR: Pioneering Titanium Production Expansion
- IperionX receives $25M in U.S. funding to accelerate titanium production
- IperionX accelerates U.S. titanium buildout
- IperionX Secures $12.5M DoD Funding for Titanium Expansion
- IperionX receives $12.5M in government funding for titanium production